Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tazarotene topical - Almirall S.A.

Drug Profile

Tazarotene topical - Almirall S.A.

Alternative Names: AGN 190168 topical; AGN-190299; Avage; Fabior; Suretin; Tazorac; Zorac

Latest Information Update: 26 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergan
  • Developer Mayne Pharma; Stiefel Laboratories
  • Class Antiacnes; Antipsoriatics; Esters; Keratolytics; Nicotinic acids; Pyrans; Pyridines; Retinoids
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Acne; Psoriasis

Highest Development Phases

  • Marketed Acne vulgaris; Photodamage; Psoriasis

Most Recent Events

  • 03 Aug 2018 Almirall S.A. acquires tazarotene topical from Allergan
  • 12 Jun 2015 Launched for Acne vulgaris in Slovakia, Bulgaria, Croatia, France, Greece, Serbia and Taiwan (Topical, gel) before June 2015
  • 12 Jun 2015 Launched for Psoriasis in Slovakia, Bulgaria, Croatia, France, Greece, Serbia and Taiwan (Topical, gel) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top